New: NCI-funded clinical trial search
Mednet Logo
SpecialtiesRadiation Oncology
Radiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

What is the preferred palliative regimen for elderly patients with rectal cancer who elect to forego surgery?

4
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Fox Chase Cancer Center

This is a question that comes up somewhat frequently and I don't believe really has a definitive answer. I myself have used multiple regimens in this situation. I think it really depends on the performance status and life expectancy of the particular patient. This is also a topic that may bring out ...

How do you sequence radiation and capecitabine in breast cancer patients receiving adjuvant capecitabine for residual disease after neoadjuvant chemotherapy?

21
6 Answers

Mednet Member
Mednet Member
Radiation Oncology · Mayo Clinic, Rochester, MN

According to personal communication with Dr. Masakazu Toi (June 13, 2017), the corresponding author of the CREATE-X NEJM publication, radiotherapy was administered prior to capecitabine in the majority of cases on this study. It is worth noting that in CALGB 49907, a randomized trial comparing capec...

Do you constrain the dose to the oropharynx, parotids, or oral cavity when planning HA-WBRT?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Northwestern Medicine Cancer Center Warrenville

On NRG CC001, there was no inter-arm difference in reported adverse events of oral mucositis (N=6 on conventional WBRT arm vs. N=4 on HA-WBRT arm), oral pain (N=3 on conventional WBRT arm vs. N=1 on HA-WBRT arm ), or dry mouth (N=19 on conventional WBRT arm vs. N=18 on HA-WBRT arm) (Brown et al., PM...

Do you use either memantine or hippocampal sparing technique to preserve cognitive function when giving whole brain radiotherapy?

4
7 Answers

Mednet Member
Mednet Member
Radiation Oncology · Mayo Clinic

Dr. @Dr. First Last and I put together the response below:We use memantine and hippocampal sparing technique for all brain metastasis patients who are planning to receive WBRT. This is based off the recently published phase III trial NRG CC001 that found hippocampal avoidance WBRT plus memantine res...

For patients with cT1-T3 cN0 cM0 mid/low rectal cancer seeking organ preservation, what treatment approach do you recommend?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Medical College of Wisconsin

This is an important question; however, the answer is unknown. The key outcome that should be the focal point for the best treatment option, is which treatment strategy results in the most optimal patient reported quality of life and bowel function. Currently, this remains void of prospective, rando...

Is there any role for ctDNA testing after surgery or SBRT for Stage IB NSCLC to determine the need for adjuvant chemotherapy?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Albert Einstein College of Medicine at Montefiore Medical Center

This is another emerging use for ctDNA that has shown promising results in small studies. The TRACERx consortium in the UK looked at the evolution of early NSCLC over time in 100 patients who underwent resection. They performed multi-region sampling and whole-exome sequencing and created patient-spe...

Would you offer hippocampal sparing whole brain radiation for patients with brain metastases due to ES-SCLC?

2
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Karmanos Cancer Institute - McLaren Proton Therapy Center

Until we have built-in auto-segmentation, I find the RTOG contouring atlas very helpful for manual contouring of the hippocampus. I tend to use the lateral ventricle as my main landmark, and look for the circle of gray matter located medial to it. Once I've drawn a hippocampus, I'll look at it in th...

For a patient with metastatic, poorly differentiated esophageal adenocarcinoma with an excellent systemic response to chemotherapy for 1 year, who now presents with isolated local progression and no new distant disease, would you consider treating the primary site with a higher palliative RT dose for more durable control?

2
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Memorial Sloan Kettering Cancer Center

For genuine oligoprogression limited to the primary tumor, in a patient who is otherwise fit and responding to systemic therapy at distant sites for ≥1 year, I would definitely consider a higher RT dose aimed at durable local control, not just short-term symptom relief. The exact regimen would obvio...

Are CHEK2 mutations a contraindication for breast conservation therapy with lumpectomy + RT?

3
4 Answers

Mednet Member
Mednet Member
Medical Oncology · Columbia University Medical Center

Among women with early-stage breast cancer and moderate penetrance breast cancer susceptibility genes, such as CHEK2, decisions about breast surgery are largely based upon personal preferences. According to data from large population-based studies, women with CHEK2 pathogenic variants have about a 2...

Is long term ADT now the standard of care with salvage prostate bed RT?

34
7 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Utah School of Medicine

The dreaded hormone question...After 40 years of embarking on extremely well designed randomized trials, we still are confused about the who, what, when of ADT. Will RTOG 9601 create a new care standard? As @Dr. First Last said, I think we will see increased utilization. I have been using bicalutami...